Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lymphocytes are a type of white blood cell that are a key component of the immune system, responsible for adaptive immunity. In the provided context, "LC" refers to lymphocytes that are coupled with Glypican-3 (GPC3) to form the LC/GPC3+ complex. This complex is being investigated as a novel vaccine for hepatocellular carcinoma (HCC). The LC/GPC3+ complex aims to elicit GPC3-specific antibody and cytotoxic T lymphocyte (CTL) responses, which effectively restrict proliferation and lyse GPC3-positive cultured-HCC cells, leading to durable tumor regression in preclinical models. The administration of LC/GPC3+ induces elevated levels of cytotoxic T cell bioactive factors and increases the number of infiltrating CD8+ T cells in tumor tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lymphocytes.